Statements

Insulin Hearing Will Add To Drug Pricing Momentum On Capitol Hill 

Apr 1, 2019

CSRxP Commends House Energy & Commerce Committee For Giving Voice To Read More

CSRxP Statement on Potential Big Pharma Bailout

Sep 21, 2018

“Only Big Pharma would use bipartisan opioid legislation as another Read More

CSRxP Statement On Exclusion Of Big Pharma Accountability Amendment In Appropriations Bill

Sep 13, 2018

House Misses Bipartisan Opportunity To Hold Big Pharma Accountable Read More

CSRxP Urges FDA To Finalize Guidance Critical To Lower Drug Prices

Aug 23, 2018

The Campaign for Sustainable Rx Pricing (CSRxP) today joined more than a dozen Read More

CSRxP Applauds Trump Administration’s Focus on Out-of-Control Drug Prices

Aug 21, 2018

CSRxP spokesman Will Holley released the following statement applauding the Read More

CSRxP Letter of Support for Durbin-Grassley DTC Advertising Amendment

Aug 21, 2018

Last night, Senators Durbin and Grassley filed an amendment to the Labor-HHS Read More

CSRxP Statement on CMS Changes to Medicare Part B

Aug 7, 2018

CSRxP spokesman Will Holley released the following statement following Read More

New Report Demonstrates Big Pharma’s Abuses of the Patent System

Aug 2, 2018

CSRxP spokesman Will Holley released the following statement on the release of Read More

High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma

Jul 27, 2018

CSRxP released the following statement following a week of strong Q2 earnings Read More

CSRxP on Lilly & Biogen Earnings

Jul 24, 2018

CSRxP released the following statement following the release of Eli Lilly and Read More

CSRxP Applauds Admin Focus on Drug Prices

Jul 19, 2018

CSRxP spokesman Will Holley released the following statement applauding the Read More

CSRxP Applauds FDA’s Biosimilars Action Plan

Jul 18, 2018

“We applaud Commissioner Gottlieb and the FDA for their leadership on Read More